Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Raw Materials (2021 - 2024)

Historic Raw Materials for Apellis Pharmaceuticals (APLS) over the last 4 years, with Q1 2024 value amounting to $42.1 million.

  • Apellis Pharmaceuticals' Raw Materials rose 2398.08% to $42.1 million in Q1 2024 from the same period last year, while for Mar 2024 it was $42.1 million, marking a year-over-year increase of 2398.08%. This contributed to the annual value of $32.7 million for FY2023, which is 963.92% up from last year.
  • Apellis Pharmaceuticals' Raw Materials amounted to $42.1 million in Q1 2024, which was up 2398.08% from $32.7 million recorded in Q4 2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Raw Materials peaked at $42.1 million during Q1 2024, and registered a low of $5.7 million during Q4 2021.
  • For the 4-year period, Apellis Pharmaceuticals' Raw Materials averaged around $26.3 million, with its median value being $28.0 million (2022).
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Raw Materials surged by 41916.86% in 2022, and later surged by 75.13% in 2023.
  • Apellis Pharmaceuticals' Raw Materials (Quarter) stood at $5.7 million in 2021, then skyrocketed by 419.17% to $29.8 million in 2022, then grew by 9.64% to $32.7 million in 2023, then grew by 28.62% to $42.1 million in 2024.
  • Its last three reported values are $42.1 million in Q1 2024, $32.7 million for Q4 2023, and $26.2 million during Q3 2023.